Long-lasting radionuclide therapy for advanced neuroendocrine tumors proves effective

(Society of Nuclear Medicine and Molecular Imaging) A first-in-human study presented at the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrates the benefits and safety of a new, long-lasting type of radionuclide therapy for patients with advanced, metastatic neuroendocrine tumors (NETs).

Comments
%d bloggers like this: